MedTrace Logo

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

NCT04193293 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2023-09-21

Study results available
· View outcomes & findings →

Summary

This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Conditions

Interventions

DRUG

Duvelisib

Phosphoinositide 3-kinase (PI3K) Inhibitor

BIOLOGICAL

Pembrolizumab

Immunotherapy (programmed cell death protein 1 \[PD-1\] inhibitor)

Sponsors & Collaborators

  • SecuraBio

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-12-10
Completion
2020-12-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04193293 on ClinicalTrials.gov